Allurion Technologies Inc
ALUR1.405USD
-0.095-6.33%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
10.91MMarket Cap
LossP/E TTM
More Details of Allurion Technologies Inc Company
Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.
Allurion Technologies Inc Info
Ticker SymbolALUR
Company nameAllurion Technologies Inc
IPO dateMar 29, 2021
CEOGaur (Shantanu)
Number of employees134
Security typeOrdinary Share
Fiscal year-endMar 29
Address11 Huron Dr Ste 200
CityNATICK
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code01760
Phone15086474000
Websitehttps://www.allurion.com/en
Ticker SymbolALUR
IPO dateMar 29, 2021
CEOGaur (Shantanu)
Company Executives of Allurion Technologies Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Shantanu Gaur, M.D.
Dr. Shantanu Gaur, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
62.03K
-20.50%
Mr. Larson Douglas Hudson
Mr. Larson Douglas Hudson
Independent Director
Independent Director
1.21K
+100.00%
Mr. Mike Cavanaugh
Mr. Mike Cavanaugh
Investor Relations
Investor Relations
--
--
Mr. Krishna K. Gupta
Mr. Krishna K. Gupta
Independent Director
Independent Director
--
--
Dr. Omar Syed Ishrak, Ph.D.
Dr. Omar Syed Ishrak, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Mr. Keith Johns
Mr. Keith Johns
Independent Director
Independent Director
--
--
Mr. R. Jason Richey
Mr. R. Jason Richey
Independent Director
Independent Director
--
--
Mr. Nicholas Sheridan (Nick) Lewin
Mr. Nicholas Sheridan (Nick) Lewin
Independent Director
Independent Director
--
--
Mr. Michael Davin
Mr. Michael Davin
Independent Director
Independent Director
--
--
Mr. Ojas A. Buch
Mr. Ojas A. Buch
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Shantanu Gaur, M.D.
Dr. Shantanu Gaur, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
62.03K
-20.50%
Mr. Larson Douglas Hudson
Mr. Larson Douglas Hudson
Independent Director
Independent Director
1.21K
+100.00%
Mr. Mike Cavanaugh
Mr. Mike Cavanaugh
Investor Relations
Investor Relations
--
--
Mr. Krishna K. Gupta
Mr. Krishna K. Gupta
Independent Director
Independent Director
--
--
Dr. Omar Syed Ishrak, Ph.D.
Dr. Omar Syed Ishrak, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Mr. Keith Johns
Mr. Keith Johns
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
All other countries
1.88M
55.73%
Spain
786.00K
23.26%
Italy
436.00K
12.90%
France
274.00K
8.11%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 27
Updated: Thu, Nov 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
63.60%
Leavitt Equity Partners III LP
5.00%
Armistice Capital LLC
2.00%
Romulus Capital Management, LLC
1.76%
Compute Health Sponsor LLC
1.41%
Other
26.23%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
63.60%
Leavitt Equity Partners III LP
5.00%
Armistice Capital LLC
2.00%
Romulus Capital Management, LLC
1.76%
Compute Health Sponsor LLC
1.41%
Other
26.23%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
64.19%
Corporation
6.41%
Investment Advisor
2.23%
Hedge Fund
2.16%
Individual Investor
2.03%
Venture Capital
1.89%
Other
21.09%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
68
6.53M
39.03%
+3.35M
2025Q3
70
3.18M
46.56%
+1.57K
2025Q2
85
3.18M
48.45%
-269.85K
2025Q1
86
1.95M
28.76%
+237.16K
2024Q4
84
752.22K
40.38%
-48.13K
2024Q3
168
830.35K
127.59%
-73.34K
2024Q2
179
581.38K
156.78%
+113.95K
2024Q1
186
467.42K
172.37%
-2.84M
2023Q4
188
468.03K
181.14%
+55.07K
2023Q3
189
413.41K
181.62%
-47.54K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
2.54M
32.75%
--
--
Jun 30, 2025
Leavitt Equity Partners III LP
462.76K
5.96%
+296.10K
+177.66%
Feb 19, 2025
Armistice Capital LLC
185.00K
2.38%
-206.64K
-52.76%
Jun 30, 2025
Romulus Capital Management, LLC
163.14K
2.1%
--
--
Mar 14, 2025
Compute Health Sponsor LLC
130.51K
1.68%
-1.00
-0.00%
Mar 14, 2025
Gupta (Krishna K.)
73.06K
0.94%
--
--
Mar 14, 2025
Gaur (Shantanu)
78.03K
1.01%
+8.00K
+11.42%
May 19, 2025
UBS Financial Services, Inc.
62.21K
0.8%
-19.94K
-24.27%
Jun 30, 2025
The Vanguard Group, Inc.
49.37K
0.64%
--
--
Jun 30, 2025
Olayan Investments Company Establishment
49.70K
0.64%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
Janus Henderson Small Cap Growth Alpha ETF
0%
iShares Micro-Cap ETF
Proportion0%
Janus Henderson Small Cap Growth Alpha ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 24, 2024
Merger
25→1
Dec 24, 2024
Merger
25→1
Dec 24, 2024
Merger
25→1
Dec 24, 2024
Merger
25→1
Date
Type
Ratio
Dec 24, 2024
Merger
25→1
Dec 24, 2024
Merger
25→1
Dec 24, 2024
Merger
25→1
Dec 24, 2024
Merger
25→1
FAQs
Who are the top five shareholders of Allurion Technologies Inc?
The top five shareholders of Allurion Technologies Inc are:
RTW Investments L.P. holds 2.54M shares, accounting for 32.75% of the total shares.
Leavitt Equity Partners III LP holds 462.76K shares, accounting for 5.96% of the total shares.
Armistice Capital LLC holds 185.00K shares, accounting for 2.38% of the total shares.
Romulus Capital Management, LLC holds 163.14K shares, accounting for 2.10% of the total shares.
Compute Health Sponsor LLC holds 130.51K shares, accounting for 1.68% of the total shares.
RTW Investments L.P. holds 2.54M shares, accounting for 32.75% of the total shares.
Leavitt Equity Partners III LP holds 462.76K shares, accounting for 5.96% of the total shares.
Armistice Capital LLC holds 185.00K shares, accounting for 2.38% of the total shares.
Romulus Capital Management, LLC holds 163.14K shares, accounting for 2.10% of the total shares.
Compute Health Sponsor LLC holds 130.51K shares, accounting for 1.68% of the total shares.
What are the top three shareholder types of Allurion Technologies Inc?
The top three shareholder types of Allurion Technologies Inc are:
RTW Investments L.P.
Leavitt Equity Partners III LP
Armistice Capital LLC
RTW Investments L.P.
Leavitt Equity Partners III LP
Armistice Capital LLC
How many institutions hold shares of Allurion Technologies Inc (ALUR)?
As of 2025Q4, 68 institutions hold shares of Allurion Technologies Inc, with a combined market value of approximately 6.53M, accounting for 39.03% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -7.53%.
What is the biggest source of revenue for Allurion Technologies Inc?
In FY2025Q2, the -- business generated the highest revenue for Allurion Technologies Inc, amounting to -- and accounting for --% of total revenue.
